Mortality from pulmonary hypertension in Europe 2001-2019.

Autor: Hartley A; National Heart and Lung Institute, Imperial College, Hammersmith Hospital, London, UK. adam.hartley12@imperial.ac.uk.; Medical Data Research Collaborative, London, UK. adam.hartley12@imperial.ac.uk., Singh H; Medical Data Research Collaborative, London, UK.; Division of Pulmonary and Critical Care Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Jani C; Medical Data Research Collaborative, London, UK.; Department of Medicine, Mount Auburn Hospital/Beth Israel Lahey Health, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA., Salciccioli JD; Medical Data Research Collaborative, London, UK.; Division of Pulmonary and Critical Care, Brigham and Women's Hospital, Boston, MA, USA., Shalhoub J; Medical Data Research Collaborative, London, UK.; Imperial College Healthcare NHS Trust, London, UK.; Department of Surgery and Cancer, Imperial College London, London, UK., Howard LS; National Heart and Lung Institute, Imperial College, Hammersmith Hospital, London, UK., Marshall DC; National Heart and Lung Institute, Imperial College, Hammersmith Hospital, London, UK.; Medical Data Research Collaborative, London, UK.
Jazyk: angličtina
Zdroj: BMC pulmonary medicine [BMC Pulm Med] 2024 Aug 28; Vol. 24 (1), pp. 415. Date of Electronic Publication: 2024 Aug 28.
DOI: 10.1186/s12890-024-03235-y
Abstrakt: Background: The incidence of Pulmonary Hypertension (PH) and Pulmonary Arterial Hypertension (PAH) is believed to be on the rise and is associated with poor outcomes.
Methods: We extracted age-standardized mortality rates (ASMRs) for decedents ≥ 18 years of age from the World Health Organization Mortality Database, using International Classification of Diseases 10th edition codes for PH and PAH, covering the period from 2001 to 2019. The UK and European Union countries with at least 1,000,000 inhabitants and at least 75% of available data points over the study period were included.
Results: Between 2001 and 2019, in countries with available data, the median ASMR for PH increased by + 1.19 per 1,000,000 (+ 22.51%) in females and + 0.36 per 1,000,000 (+ 6.06%) in males. Out of 19 countries, 13 demonstrate an increase in female PH ASMR, and 12 reported an increase in male PH ASMR. In contrast, median PAH ASMR decreased by -0.29 per 1,000,000 (-28.74%) in females and remained relatively unchanged in males, with a minor increase of + 0.01 per 1,000,000 (+ 1.07%). Notably, there was significant inter-country heterogeneity, with countries such as Hungary, Romania, and Poland displaying results incongruous with the rest of Europe.
Conclusions: While publicly available mortality statistics for PH may be unreliable, these data suggest an overall increase in mortality across Europe from 2001 to 2019. However, mortality from PAH has shown a decrease in females and a modest increase in males. This underscores the urgent need for robust and high-quality mortality reporting, including international registries, for both PH and PAH.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: